Exagen's Raised Outlook Faces Its First Test As Street Models A Sequential Revenue Dip

Exagen heads into its third-quarter report with an unusual mismatch between what management is promising and what Wall Street is modeling. The company recently lifted its 2026 revenue outlook to a range of $72.0 million to $75.0 million, up from $70.0 million to $73.0 million. Yet the full-year consensus of $71.7 million still sits below the bottom of that new range. In other words, analysts have not fully bought the raise. That gap, together with a stock that has climbed sharply since the last report, makes this a quarter where the details matter more than usual.

For the September quarter, analysts expect revenue of about $18.3 million, up roughly 6% from $17.2 million a year earlier, along with a loss of $0.19 per share, unchanged from the year-ago period. That is modest growth, not a breakout. More telling is the sequential picture. Exagen posted $19.9 million in revenue and a loss of $0.13 per share last quarter, so consensus implies revenue falling by more than $1.5 million and the loss widening. Some quarter-to-quarter noise is normal in a diagnostics business, where results reflect both how many AVISE tests are processed and how much the company collects per test. But a decline of that size would be hard to square with a company that just told investors to expect more for the year, not less.

That is the crux of the setup. If management truly sees revenue landing between $72 million and $75 million, the third quarter needs to look closer to the prior quarter's run rate than to the Street's figure. A result near $19 million or higher would support the view that the raised guidance reflects durable momentum rather than one strong quarter. A print near or below consensus, on the other hand, would put more weight on the fourth quarter to hit the range and invite questions about whether the second quarter was flattered by timing or one-time collections. Investors should also look at whether management reaffirms, nudges up or quietly narrows the outlook. Reiterating the range after a soft quarter would imply a demanding year-end ramp, which tends to make a market nervous.

The bottom line deserves attention too. Exagen remains unprofitable, and the move from a $0.13 loss last quarter to an expected $0.19 loss suggests analysts anticipate either lower revenue absorption or higher spending. If revenue holds up and expenses stay contained, the loss could come in meaningfully narrower than forecast, which would reinforce the idea that scale is starting to work in the company's favor.

Expectations around the stock have shifted. Shares have gained about 46% since the last report, while the S&P 500 slipped about 1%, a 47-point margin of outperformance. At $8.39, the stock trades well above its 200-day moving average of $5.04, and its entire post-earnings range of $5.74 to $9.22 sits above the prior quarter's $3.08 to $5.55 band. It is about 9% below the recent high, so this is not a breakout setup, but the rerating is substantial. Interestingly, sentiment has cooled from mildly bullish heading into last quarter to modestly bearish now, suggesting some investors worry the rally has run ahead of the fundamentals.

The central question is simple: does the third quarter look like a company on track for $72 million to $75 million, or one leaning heavily on a hoped-for finish? Revenue that holds near last quarter's level, paired with confirmation of the raised outlook, would keep the growth story intact and justify much of the recent move. A sequential slide that matches the Street's caution would leave the guidance looking stretched and the stock's gains exposed.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.